Update in cystic fibrosis 2013

American Journal of Respiratory and Critical Care Medicine

Volumn 189, Issue 10, 2014, Pages 1181-1186

  Jain, Manu ^a,b   Goss, Christopher H ^c,d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CHLORIDE; CIGARETTE SMOKE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GLUTATHIONE; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; IVACAFTOR; LEUKOCYTE ELASTASE; PLACEBO;

ADAPTIVE IMMUNITY; ADULT RESPIRATORY DISTRESS SYNDROME; AGENESIS; AIRWAY RESISTANCE; ARTICLE; ASTHMA; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC SINUSITIS; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DRUG EFFICACY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; FUNGUS GROWTH; GENE MUTATION; GRAFT SURVIVAL; HUMAN; IN VITRO STUDY; INNATE IMMUNITY; ION CURRENT; LIFE EXPECTANCY; LOBAR PNEUMONIA; LUNG CLEARANCE; LUNG LAVAGE; LUNG TRANSPLANTATION; LUNG VOLUME; MACROMOLECULE; MECHANICAL VENTILATOR; MECONIUM ILEUS; MUCOCILIARY CLEARANCE; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM INTRACELLULARE AVIUM; NEUTROPHIL; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PANCREAS FUNCTION; PANCREATITIS; PATHOPHYSIOLOGY; PH; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PILOT STUDY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM BIOPSY; REGULATORY T LYMPHOCYTE; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFECTION; RISK FACTOR; SMOKING; SPIROMETRY; SPUTUM VISCOSITY; STABLE EXPRESSION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; T LYMPHOCYTE; TH17 CELL; TREATMENT DURATION; TRYPTOPHAN METABOLISM; UNFOLDED PROTEIN RESPONSE; UNSPECIFIED SIDE EFFECT; VAS DEFERENS;

AMINOPHENOLS; BRONCHIECTASIS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EVIDENCE-BASED MEDICINE; HUMANS; LIFE EXPECTANCY; MUTATION; OXIDATIVE STRESS; PREVALENCE; QUINOLONES; RISK ASSESSMENT; RISK FACTORS; SMOKING;

EID: 84901008941     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201402-0203UP     Document Type: Article

References (48)

1. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation patient registry 2012 annual data report. Bethesda, MD: Cystic Fibrosis Foundation; 2013.
2. Clancy JP, Jain M. Personalized medicine in cystic fibrosis: dawning of a new era. Am J Respir Crit Care Med 2012;186:593-597.
3. Davies JC, Wainwright CE, Canny GJ, Chilvers MA, Howenstine MS, Munck A, Mainz JG, Rodriguez S, Li H, Yen K, et al.; VX08-770-103 (ENVISION) Study Group. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 2013;187: 1219-1225.
4. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřev́inek P, Griese M, McKone EF, Wainwright CE, Konstan MW, et al.; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365: 1663-1672.
5. Pezzulo AA, Tang XX, Hoegger MJ, Alaiwa MH, Ramachandran S, Moninger TO, Karp PH, Wohlford-Lenane CL, Haagsman HP, van Eijk M, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 2012;487:109-113.
6. DiMango E, Ratner AJ, Bryan R, Tabibi S, Prince A. Activation of NFkappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J Clin Invest 1998;101: 2598-2605.
7. Jayaraman S, Joo NS, Reitz B, Wine JJ, Verkman AS. Submucosal gland secretions in airways from cystic fibrosis patients have normal [Na(1)] and pH but elevated viscosity. Proc Natl Acad Sci USA 2001;98: 8119-8123.
8. Goldstein W, Döring G. Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis. Am Rev Respir Dis 1986;134:49-56.
9. Nakamura H, Yoshimura K, McElvaney NG, Crystal RG. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest 1992;89:1478-1484.
10. Chen EY, Yang N, Quinton PM, Chin WC. A new role for bicarbonate in mucus formation. Am J Physiol Lung Cell Mol Physiol 2010;299: L542-L549.
11. Adam RJ, Michalski AS, Bauer C, Abou Alaiwa MH, Gross TJ, Awadalla MS, Bouzek DC, Gansemer ND, Taft PJ, Hoegger MJ, et al. Air trapping and airflow obstruction in newborn cystic fibrosis piglets. Am J Respir Crit Care Med 2013;188:1434-1441.
12. Stoltz DA, Meyerholz DK, Pezzulo AA, Ramachandran S, Rogan MP, Davis GJ, Hanfland RA, Wohlford-Lenane C, Dohrn CL, Bartlett JA, et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med 2010;2:29ra31.
13. Teague WG. Trouble from the start: airway structural anomalies present at birth in the cystic fibrosis piglet. Am J Respir Crit Care Med 2013; 188:1391-1392.
14. Trezise AE, Chambers JA, Wardle CJ, Gould S, Harris A. Expression of the cystic fibrosis gene in human foetal tissues. Hum Mol Genet 1993;2:213-218.
15. Sly PD, Gangell CL, Chen L, Ware RS, Ranganathan S, Mott LS, Murray CP, Stick SM; AREST CF Investigators. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 2013; 368:1963-1970.
16. Cantin AM, Hanrahan JW, Bilodeau G, Ellis L, Dupuis A, Liao J, Zielenski J, Durie P. Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am J Respir Crit Care Med 2006;173:1139-1144.
17. Raju SV, Jackson PL, Courville CA, McNicholas CM, Sloane PA, Sabbatini G, Tidwell S, Tang LP, Liu B, Fortenberry JA, et al. Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function. Am J Respir Crit Care Med 2013;188:1321-1330.
18. Crystal RG. Are the smoking-induced diseases an acquired form of cystic fibrosis? Am J Respir Crit Care Med 2013;188:1277-1278.
19. Moskwa P, Lorentzen D, Excoffon KJ, Zabner J, McCray PB Jr, Nauseef WM, Dupuy C, Bánfi B. A novel host defense system of airways is defective in cystic fibrosis. Am J Respir Crit Care Med 2007;175:174-183.
20. Sagel SD, Wagner BD, Anthony MM, Emmett P, Zemanick ET. Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. Am J Respir Crit Care Med 2012;186: 857-865.
21. Mayer-Hamblett N, Aitken ML, Accurso FJ, Kronmal RA, Konstan MW, Burns JL, Sagel SD, Ramsey BW. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med 2007;175:822-828.
22. Le Gars M, Descamps D, Roussel D, Saussereau E, Guillot L, Ruffin M, Tabary O, Hong SS, Boulanger P, Paulais M, et al. Neutrophil elastase degrades cystic fibrosis transmembrane conductance regulator via calpains and disables channel function in vitro and in vivo. Am J Respir Crit Care Med 2013;187:170-179.
23. Vij N, Downey GP. The yin and yang of cystic fibrosis transmembrane conductance regulator function: implications for chronic lung disease. Am J Respir Crit Care Med 2013;187:120-122.
24. Mueller C, Braag SA, Keeler A, Hodges C, Drumm M, Flotte TR. Lack of cystic fibrosis transmembrane conductance regulator in CD31 lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses. Am J Respir Cell Mol Biol 2011;44:922-929.
25. Regamey N, Tsartsali L, Hilliard TN, Fuchs O, Tan HL, Zhu J, Qiu YS, Alton EW, Jeffery PK, Bush A, et al. Distinct patterns of inflammation in the airway lumen and bronchial mucosa of children with cystic fibrosis. Thorax 2012;67:164-170.
26. Tiringer K, Treis A, Fucik P, Gona M, Gruber S, Renner S, Dehlink E, Nachbaur E, Horak F, Jaksch P, et al. A Th17-and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2013;187:621-629.
27. Iannitti RG, Carvalho A, Cunha C, De Luca A, Giovannini G, Casagrande A, Zelante T, Vacca C, Fallarino F, Puccetti P, et al. Th17/Treg imbalance in murine cystic fibrosis is linked to indoleamine 2,3-dioxygenase deficiency but corrected by kynurenines. Am J Respir Crit Care Med 2013;187:609-620.
28. Robinson KM, Alcorn JF. T-cell immunotherapy in cystic fibrosis: weighing the risk/reward. Am J Respir Crit Care Med 2013;187: 564-566.
29. Iannitti RG, Casagrande A, De Luca A, Cunha C, Sorci G, Riuzzi F, Borghi M, Galosi C, Massi-Benedetti C, Oury TD, et al. Hypoxia promotes danger-mediated inflammation via receptor for advanced glycation end products in cystic fibrosis. Am J Respir Crit Care Med 2013;188:1338-1350.
30. McGuire JK. Hypoxia, receptor for advanced glycation end products, and cystic fibrosis: a pathway to chronic inflammation? Am J Respir Crit Care Med 2013;188:1280-1281.
31. Aurora P, Stanojevic S, Wade A, Oliver C, Kozlowska W, Lum S, Bush A, Price J, Carr SB, Shankar A, et al.; London Cystic Fibrosis Collaboration. Lung clearance index at 4 years predicts subsequent lung function in children with cystic fibrosis. Am J Respir Crit Care Med 2011;183:752-758.
32. Irving SJ, Ives A, Davies G, Donovan J, Edey AJ, Gill SS, Nair A, Saunders C, Wijesekera NT, Alton EW, et al. Lung clearance index and high-resolution computed tomography scores in primary ciliary dyskinesia. Am J Respir Crit Care Med 2013;188:545-549.
33. Belessis Y, Dixon B, Hawkins G, Pereira J, Peat J, MacDonald R, Field P, Numa A, Morton J, Lui K, et al. Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index. Am J Respir Crit Care Med 2012;185:862-873.
34. Subbarao P, Stanojevic S, Brown M, Jensen R, Rosenfeld M, Davis S, Brumback L, Gustafsson P, Ratjen F. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis: a pilot study using inhaled hypertonic saline. Am J Respir Crit Care Med 2013;188:456-460.
35. Rosenfeld M, Ratjen F, Brumback L, Daniel S, Rowbotham R, McNamara S, Johnson R, Kronmal R, Davis SD; ISIS Study Group. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA 2012; 307:2269-2277.
36. Beydon N, Robinson PD. Early intervention for newborns screened for cystic fibrosis. Am J Respir Crit Care Med 2013;188:409-410.
37. Davies J, Sheridan H, Bell N, Cunningham S, Davis SD, Elborn JS, Milla CE, Starner TD, Weiner DJ, Lee PS, et al. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial. Lancet Respir Med 2013; 1:630-638.
38. Odolczyk N, Fritsch J, Norez C, Servel N, da Cunha MF, Bitam S, Kupniewska A, Wiszniewski L, Colas J, Tarnowski K, et al. Discovery of novel potent DF508-CFTR correctors that target the nucleotide binding domain. EMBO Mol Med 2013;5:1484-1501.
39. Griese M, Kappler M, Eismann C, Ballmann M, Junge S, Rietschel E, van Koningsbruggen-Rietschel S, Staab D, Rolinck-Werninghaus C, Mellies U, et al.; Glutathione Study Group. Inhalation treatment with glutathione in patients with cystic fibrosis: a randomized clinical trial. Am J Respir Crit Care Med 2013;188:83-89.
40. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME; The Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-642.
41. Dubois AV, Midoux P, Gras D, Si-Tahar M, Bréa D, Attucci S, Khelloufi MK, Ramphal R, Diot P, Gauthier F, et al. Poly-L-lysine compacts DNA, kills bacteria, and improves protease inhibition in cystic fibrosis sputum. Am J Respir Crit Care Med 2013;188:703-709.
42. Rubin BK. Faster, higher, stronger. Am J Respir Crit Care Med 2013; 188:634-635.
43. Aitken ML, Limaye A, Pottinger P, Whimbey E, Goss CH, Tonelli MR, Cangelosi GA, Dirac MA, Olivier KN, Brown-Elliott BA, et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med 2012;185:231-232.
44. Bryant JM, Grogono DM, Greaves D, Foweraker J, Roddick I, Inns T, Reacher M, Haworth CS, Curran MD, Harris SR, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 2013;381:1551-1560.
45. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW III; Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-1756.
46. Binder AM, Adjemian J, Olivier KN, Prevots DR. Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Am J Respir Crit Care Med 2013;188:807-812.
47. Thabut G, Christie JD, Mal H, Fournier M, Brugière O, Leseche G, Castier Y, Rizopoulos D. Survival benefit of lung transplant for cystic fibrosis since lung allocation score implementation. Am J Respir Crit Care Med 2013;187:1335-1340.
48. Garrity ER Jr. Should adults with cystic fibrosis receive lung transplants? Outcomes versus progression of disease. Am J Respir Crit Care Med 2013;187:1283-1284.